Indeed, current findings indicate that the presence of CD8+ T cells is predictive of anti-PD-1 therapeutic responses in malignancies such as non-small-cell lung carcinoma and melanoma (43). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.